SCHEDULE: Janus Henderson Discloses 10.1% Stake in Relmada Therapeutics

Janus Henderson Group plc has reported a 10.1% beneficial ownership stake in Relmada Therapeutics, Inc., holding 7,439,415 shares of common stock.

Summary

• Janus Henderson Group plc, through its various asset managers, beneficially owns 7,439,415 shares of Relmada Therapeutics, Inc. common stock.
• This ownership represents 10.1% of the class of Relmada Therapeutics' common stock.
• Janus Henderson Group plc and its asset managers have shared voting power and shared dispositive power over all 7,439,415 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Relmada Therapeutics.
• The Janus Henderson Biotech Innovation Master Fund Ltd. is identified as a Managed Portfolio with the right to receive dividends or proceeds from the sale of more than five percent of Relmada Therapeutics' ordinary shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating significant institutional investor interest in Relmada Therapeutics, which can often be a precursor to increased market confidence.

Positives

• Significant institutional ownership by a major asset manager like Janus Henderson Group plc can signal confidence in Relmada Therapeutics' long-term prospects.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests a belief in the company's current strategy without intent for control.

Risks

• Janus Henderson Group plc and its Asset Managers disclaim any ownership associated with the right to receive dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios.

Future Outlook

This filing does not contain forward-looking statements or guidance from Relmada Therapeutics, Inc. It is a disclosure of beneficial ownership by an institutional investor.

Management Comments

• Janus Henderson Group plc certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that a substantial stake from a prominent asset manager like Janus Henderson Group plc can often be interpreted by the market as a vote of confidence in the underlying company, particularly in the often volatile biotech sector. This institutional interest may attract further investor attention to Relmada Therapeutics.

Comparison to Industry Standards

• This 10.1% stake is a significant position for an institutional investor in a company like Relmada Therapeutics, indicating a strong conviction in its potential.
• Compared to typical institutional holdings, a 10% stake is substantial enough to be a top holding in many diversified funds, reflecting a concentrated bet on Relmada's future performance.

Stakeholder Impact

• Shareholders may view this as a positive indicator of institutional confidence in Relmada Therapeutics, potentially leading to increased investor interest and stability in the stock.

Key Dates

Recommendation

The disclosure of a significant 10.1% passive stake by a major asset manager like Janus Henderson Group plc indicates institutional confidence in Relmada Therapeutics. While this filing does not provide operational or financial performance updates, such a substantial investment by a reputable firm often signals a positive long-term outlook, warranting a 'hold' recommendation for existing investors and potential consideration for new investors to research further.

Keywords

Relmada Therapeutics, Janus Henderson, Institutional Ownership, Common Stock, Schedule 13G, Biotech, Investment, Passive Investment